Key result
Large ASCVD randomized trials exhibit substantial heterogeneity across reported primary endpoints.
Answers are grounded in this paper and cite their sources.
This study highlights the heterogeneity in primary endpoints used across large atherosclerotic cardiovascular disease trials published in prominent journals.
This cohort study examines heterogeneity in primary end points reported by randomized clinical trials of atherosclerotic cardiovascular disease published in prominent medical journals.
No takes yet. Share an insight, caveat, or question.
Shepshelovich et al. (2025) studied this question. Large randomized clinical trials of atherosclerotic cardiovascular disease exhibit heterogeneity in their reported primary end points.
Synapse has enriched 10 related papers. Consider them for comparative context: